Y Wang1, Y Zhang2. 1. Department of Urologic Surgery, Yantai Affiliated Hospital of Binzhou Medical University, No. 717, Jinbu Street, Muping District, Yantai, Shandong, 264100, China. ylwang_med@126.com. 2. Office of Quality Assurance and Safety Management, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, Shandong, 264100, China.
Abstract
BACKGROUND: To evaluate the prognostic role of interleukin-6 (IL-6) in renal cell carcinoma (RCC). METHOD: Relevant research articles were obtained from literature databases. Data were extracted from study reports which reported IL-6 levels in relevance to RCC prognosis and random-effects meta-analyses were performed to estimate IL-6 levels, percentage of patients with high IL-6 levels, and hazard/odds ratios between high and low IL-6 levels in survival outcomes. RESULTS: 22 studies (1976 patients; age 59.9 years [95% confidence interval (CI) 58.0, 61.8]; 33% [95% CI 29, 36] females) were included. IL-6 levels in RCC patients ranged from 8.9 ± 13-193 ± 101 picograms per milliliter (pg/ml) which were higher than those of normal healthy individuals (mean difference 13.96 pg/ml [95% CI: 1.52, 26.40]; p = 0.03). Percentage of RCC patients with high IL-6 levels was 48.98% [95% CI 42.94, 55.03] and this rate was greater in advanced (51.73% [95% CI 45.94, 57.53]) than in local (40.75% [95% CI 26.23, 55.27]) RCC. Survival was longer in patients with low compared to high IL-6 levels (MD 9.65 months [95% CI 5.01, 14.29]; p < 0.0006 and hazard ratio 3.03 [95% CI 2.37, 3.70]). Treatment response rate was significantly higher in patients with low IL-6 than high IL-6 levels (odds ratio 5.11 [95% CI 2.21, 11.77]; p < 0.00001). There was a strong correlation between IL-6 and c-reactive protein levels (correlation coefficient 0.622 [95% CI 0.431, 0.760]; p = 0.00001). CONCLUSION: IL-6 levels are much variable in RCC patients. High levels of IL-6 in RCC patients are associated with poor survival.
BACKGROUND: To evaluate the prognostic role of interleukin-6 (IL-6) in renal cell carcinoma (RCC). METHOD: Relevant research articles were obtained from literature databases. Data were extracted from study reports which reported IL-6 levels in relevance to RCC prognosis and random-effects meta-analyses were performed to estimate IL-6 levels, percentage of patients with high IL-6 levels, and hazard/odds ratios between high and low IL-6 levels in survival outcomes. RESULTS: 22 studies (1976 patients; age 59.9 years [95% confidence interval (CI) 58.0, 61.8]; 33% [95% CI 29, 36] females) were included. IL-6 levels in RCCpatients ranged from 8.9 ± 13-193 ± 101 picograms per milliliter (pg/ml) which were higher than those of normal healthy individuals (mean difference 13.96 pg/ml [95% CI: 1.52, 26.40]; p = 0.03). Percentage of RCCpatients with high IL-6 levels was 48.98% [95% CI 42.94, 55.03] and this rate was greater in advanced (51.73% [95% CI 45.94, 57.53]) than in local (40.75% [95% CI 26.23, 55.27]) RCC. Survival was longer in patients with low compared to high IL-6 levels (MD 9.65 months [95% CI 5.01, 14.29]; p < 0.0006 and hazard ratio 3.03 [95% CI 2.37, 3.70]). Treatment response rate was significantly higher in patients with low IL-6 than high IL-6 levels (odds ratio 5.11 [95% CI 2.21, 11.77]; p < 0.00001). There was a strong correlation between IL-6 and c-reactive protein levels (correlation coefficient 0.622 [95% CI 0.431, 0.760]; p = 0.00001). CONCLUSION:IL-6 levels are much variable in RCCpatients. High levels of IL-6 in RCCpatients are associated with poor survival.
Authors: N Thiounn; F Pages; T Flam; E Tartour; V Mosseri; M Zerbib; P Beuzeboc; L Deneux; W H Fridman; B Debré Journal: Immunol Lett Date: 1997-07 Impact factor: 3.685
Authors: A J Zurita; E Jonasch; X Wang; M Khajavi; S Yan; D Z Du; L Xu; M H Herynk; K S McKee; H T Tran; C J Logothetis; N M Tannir; J V Heymach Journal: Ann Oncol Date: 2011-04-04 Impact factor: 32.976
Authors: Emiliano Calvo; Manuela Schmidinger; Daniel Y C Heng; Viktor Grünwald; Bernard Escudier Journal: Cancer Treat Rev Date: 2016-09-10 Impact factor: 12.111
Authors: Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri Journal: J Clin Oncol Date: 2009-10-13 Impact factor: 44.544
Authors: N Yoshida; S Ikemoto; K Narita; K Sugimura; S Wada; R Yasumoto; T Kishimoto; T Nakatani Journal: Br J Cancer Date: 2002-05-06 Impact factor: 7.640